NCT00203216View on ClinicalTrials.gov

A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

January 31, 2005

Study Completion Date

September 30, 2005

Conditions
Migraine
Interventions
DRUG

levetiracetam

Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)

PROCEDURE

Transcranial Magnetic Stimulation

Trial Locations (1)

19107

Jefferson Headache Center, Philadelphia

Sponsors

Collaborators (1)

UCB Pharma
All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

Thomas Jefferson University

OTHER